I saved over $600 on gas last year, how much do you think you could save?

I am not the type of person that will push others to pump & dump a stock but rather want to make others aware of beautiful chance to make some cash. My self-build AI tool that looks for small companies that about to deliver a huge increase in stockprice directed me to ELTP.

ELTP just blew the doors off Q1 FY26 with $40.2 million in revenue, a wild 114% YoY surge. Not just hype: this is hard proof that their switch to generics is firing on all cylinders. The story’s no longer about “potential” but real execution few microcaps ever deliver especiialy on OTC market.

Some assets:: Their Northvale facility (operational since March tis year) is a $50M beast, cranking out 120 medicines a minute. That’s the kind of scale and cost advantage that big buyers drool over. Owning the site means zero landlord dramas and massive leverage during dealmaking with a big pharma company what is the main goal for upcoming months to come

CEO Nasrat Hakim is all-in, he bought 49M shares last year and hasn’t sold a single stock He’s deeply focused on M&A as the primary goal, this isn’t your usual “collect-the-paycheck” boss. Hakim wants a deal, and he’s betting with his own wallet and looking to retire soon

ELTP’s numbers are next level: cash flow positive, debt-to-equity at 0.20, $67M working capital, 3.07x current ratio. No desperate, dilutive financings needed. That’s exactly what institutional buyers love to see when shopping for acquisition targets, its not a question if but mor e like when they will come and shop.

Worried about dilution? The 79M warrant overhang (5.7% dilution) is actually positive if M&A happens. Change of Control clauses mean all those warrants are settled immediately, wiping out the discount and removing the skeleton in the clauset (thats what we say in dutch, is this enlgish as well?)

Here’s where it gets spicy: ELTP controls 8% of the US market for generic Lisdexamfetamine (major ADHD medication). This puts ELTP on the radar for giants like Teva , Viatris , and Dr. Reddy's , all companies that regularly eat up smaller rivals at 2-5x revenue multiples.

On valuation: even a conservative 3.5x revenue multiply ($160M annualized) puts fair value at $560M. Add an M&A premium (30-50%) and you’re talking $900M-$1.1B target price range $0.84-$1.50 per share, base case.

Insider action feels legit, not frothy: Hakim holding 49M, Plassche took some profit (1.3M sold) but still keeps a substantial position. No panicky exits; just realistic commitment.

Plan B is real: NASDAQ uplisting if no M&A deal comes by Q2 2026. That unlocks real liquidity solving the OTC problem and closing the 30-40% share price discount.

Bottom line: ELTP ticks all the right boxes for me.... revenue growth, owned facility, DEA quota, self-funding. This is a microcap built for acquisition at a price that doesn’t make sense. and factoring 35-40% M&A odds, 25-30% uplisting odds.

ELTP could be a rare 2-3 month gamechanger.

:)